Skip to content

Research on the Clinical Characteristics and Key Diagnosis and Treatment Technology of Genetic and Metabolic Liver Disease

Research on the Clinical Characteristics and Key Diagnosis and Treatment Technology of Genetic and Metabolic Liver Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05601557
Enrollment
480
Registered
2022-11-01
Start date
2022-12-01
Completion date
2025-04-30
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis , Treatment, Genetic and Metabolic Liver Disease

Brief summary

1. Establish a follow-up cohort of genetic and metabolic liver disease in The Chinese population, and carry out research on disease spectrum, clinical characteristics and personalized diagnosis and treatment to improve the level of diagnosis and treatment. 2. Establish a multidisciplinary collaborative diagnosis and treatment model of genetic metabolic liver disease, develop and promote diagnosis and treatment paths, and improve the diagnosis and treatment ability of genetic metabolic liver disease in Beijing and even the whole country. 3. Establish a new CRISPR gene diagnosis technology to realize fast and low-cost genetic testing. 4. Elucidating the genetic mutation spectrum of common genetic and metabolic liver disease in China is helpful to accurate gene diagnosis and functional research. 5. Study the genotype-phenotype, mutation and clinical outcome relationship and influencing factors of the common genetic and metabolic liver disease population in China, to guide the early diagnosis, early treatment and improve the prognosis.

Interventions

OTHERThere is no intervention

The genotype of the patients was analyzed.

Sponsors

Sujun Zheng
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Meet the diagnostic criteria of each disease.

Exclusion criteria

1. Co-infected with hepatitis B virus, hepatitis C virus and HIV; 2. Patients with liver fibrosis and cirrhosis caused by other causes; 3. Patients with alcoholic liver disease and autoimmune liver disease; 4. Liver malignancy has been suggested or confirmed by evidence; 5. Combined with other serious systemic diseases.

Design outcomes

Primary

MeasureTime frameDescription
death5 yearsDeath during the study was the outcome event

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026